Public release date: 31-Jul-2013 [ | E-mail | Share ] Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine The Icahn School of Medicine at Mount Sinai is partnering with the Institute for Family Health to launch the first-ever genetic testing program in the primary care setting to identify genetic risk for kidney disease in patients with hypertension. The program will be funded through a $3.7 million grant from the National Human Genome Research Institute of the National Institutes of Health. Primary-care providers will use patients' genomic information at the point-of-care to individualize treatment, testing and monitoring with Mount Sinai's Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomic Program, or CLIPMERGE, a novel clinical-decision support engine for delivering guidelines with genetic variants of clinical significance to enhance treatment. Recent research has shown that one in eight African Americans have two copies of a version of the APOL1 gene, putting them at four to five times greater risk for developing chronic kidney disease or end-stage kidney disease if they have hypertension, or high blood pressure. "Many patients do not have their blood pressure adequately controlled," said Erwin Bottinger, MD, Director … Continue reading →

SAN DIEGO and IRVINE, Calif., Aug. 1, 2013 /PRNewswire/ -- Sequenom, Inc. (SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation (CBMX), a molecular diagnostics laboratory performing DNA-based testing services for developmental disorders and cancer, today jointly announced that the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to broaden and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients. Under the agreement, the two laboratories will collaboratively use their respective marketing channels and sales forces to promote the use of NIPT and CMA and work together to provide technical training to physicians and counseling, education and support services to physicians and their patients. The two companies plan to provide, when clinically appropriate, a comprehensive test result report for ordering physicians. Sequenom is a global leader in the NIPT market, and Sequenom CMM, its wholly owned subsidiary laboratory, developed the MaterniT21TM PLUS laboratory-developed test (LDT), a widely-ordered, noninvasive prenatal testing service for fetal chromosomal abnormalities. CombiMatrix is one of the few independent laboratories that specialize in CMA, the primary genetic test to evaluate … Continue reading →

July 31, 2013 Recent technological developments in genomics have revealed a large number of genetic influences on common complex diseases, such as diabetes, asthma, cancer or schizophrenia. However, discovering a genetic variant predisposing to a disease is only a first step. To apply this knowledge towards prevention or cure, including tailoring treatment to the patient's genetic profile -also known as personalized medicine -- we need to know how this genetic variant affects health. In a study published today in Nature Communications, Dr. Constantin Polychronakos from the Research Institute of the McGill University Health Centre (RI-MUHC), and collaborators from McGill University and The University of Texas, propose a novel approach for scanning the entire genome that will help us understand the effect of genes on human traits. "This completely new methodology really opens up different ways of understanding how the genome affects the biology of the human body," says Dr. Polychronakos, corresponding author of the study and Director of the Endocrine Genetics Laboratory at the Montreal Children's Hospital and Professor in the Departments of Pediatrics and Human Genetics at McGill University. DNA is the blueprint according to which our body is constructed and functions. Cells "read" this blueprint by transcribing the … Continue reading →

Newswise The Icahn School of Medicine at Mount Sinai is partnering with the Institute for Family Health to launch the first-ever genetic testing program in the primary care setting to identify genetic risk for kidney disease in patients with hypertension. The program will be funded through a $3.7 million grant from the National Human Genome Research Institute of the National Institutes of Health. Primary-care providers will use patients genomic information at the point-of-care to individualize treatment, testing and monitoring with Mount Sinais Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomic Program, or CLIPMERGE, a novel clinical-decision support engine for delivering guidelines with genetic variants of clinical significance to enhance treatment. Recent research has shown that one in eight African Americans have two copies of a version of the APOL1 gene, putting them at four to five times greater risk for developing chronic kidney disease or end-stage kidney disease if they have hypertension, or high blood pressure. Many patients do not have their blood pressure adequately controlled, said Erwin Bottinger, MD, Director of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and one of two principal investigators of the grant. … Continue reading →

Stem Cell Therapy - Amazing Breakthrough in Skin wrinkles treatment Stem Cell Therapy is the newest bio-active topical cream that actually stimulates your own existing skin stem cells to grow smooth, supple, firm new skin. Fo... By: Buystemcell.com.au … Continue reading →

JUPITER, Fla., Aug. 1, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on stem cell-based therapeutics, today announced the issuance of a shareholder letter by Chief Executive Officer,Mark Weinreb, providing an update to shareholders on the Company's progress. The shareholders were advised as follows: Over the past 12 months, BRT's substantial investment in research and development has allowed the Company to continue executing on its growth strategy. There have been many developments, both operationally and scientifically, that have positioned the Company well as a growing stem cell biotechnology company with a specific focus on cellular treatments and therapies for certain medical applications. Below are some of the Company's accomplishments and activities over the past 12 months: "Based on these accomplishments, we are excited for what lies ahead in the near and long term," states CEO Mark Weinreb. "We continue to make speedy and efficient progress with our programs and look forward to further advancements regarding each of our exciting initiatives. I would like to thank all of our shareholders for their continued support. We will continue to work diligently to further execute our growth plan so that BioRestorative Therapies will … Continue reading →

Marcelle Noble, of Queenstown Regenerative Medicine, and Prof Richard Boyd, of Monash University in Melbourne. Photo by Christina McDonald. It will start treating sportsmen and those with osteoarthritis, with the intention to later treating people with multiple sclerosis and diabetes. Richard Boyd, of Monash University, Melbourne, yesterday told delegates at the New Zealand College of Appearance Medicine conference, being held in the resort, about his plans for a centre in Queenstown. The centre would be an extension of Queenstown Regenerative Medicine (QRM) and a collaboration between the resort's regenerative medicine movers and shakers, Marcelle Noble and Peter Britton, John Flynn, of the Gold Coast, and Prof Boyd. Prof Boyd is the director of immunology and stem cell laboratories at Monash. Ms Noble, owner and director of QRM, said discussions were under way for a purpose-built centre, funded by private investors. The location was likely to be near the Remarkables Park Shopping Centre. A cryopreservation facility to store stem cells, umbilical cord blood and amnion is expected to be a future development. Prof Boyd said Queenstown's mixture of types and quantity of sports injuries and proactive people involved in regenerative medicine were major reasons for choosing the resort. A procedure (platelet … Continue reading →

"Green" method to create antibacterial gold nanoparticles for potential medical use with the help of common eucalyptus leaves. Murdoch University researchers have developed a green method to create antibacterial gold nanoparticles for potential use in the medical field with the help of common eucalyptus leaves. Dr Gerrard Eddy Poinern, Director of the Murdoch Applied Nanotechnology Research Group (MANRG), said gold nanometre scale particles were on the leading-edge of health innovation. Gold nanoparticles have proven to be very versatile across a range of treatments, including in the delivery of double-stranded DNA in the emerging gene therapy area, Dr Poinern said. They can also be passively accumulated in tumours for thermal treatment therapies, where they are heated to damage and kill cancer cells. And studies have shown that cancer drugs bonded to the surface of gold nanoparticles can effectively target tumours, improving delivery and minimising treatment durations and the side effects of anticancer drugs. Dr Poinern said, however, that up until recently, the particles production had involved expensive chemical and physical processes that often used toxic materials with potential hazards such as environmental toxicity, cytotoxicity and carcinogenicity. Thanks to the Eucalyptus macrocarpa, were changing that. Our method is water-based, performed at room … Continue reading →